Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs Cassava Sciences Inc (FLNA) Price & Performance

Global X Robotics and Artificial Intelligence ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Global X Robotics and Artificial Intelligence ETF vs Cassava Sciences Inc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $36.05, while Cassava Sciences Inc trades at $1.11 (market cap $52.66M). The key difference: Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

BOTZFLNA
52-Week High
$41.63$4.64
52-Week Low
$31.99$1.09
Market Cap
$52.66M
Sector
Health
Enterprise Value
-$33.92M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Robotics and Artificial Intelligence ETF

BOTZ trades at $35.87, down 2.82% with a bearish technical outlook showing 16 sell signals versus 3 buy signals. The ETF faces headwinds despite positive industry sentiment around robotics and AI growth. Recent news highlights robotics as the next frontier beyond chatbots, with humanoid robots projected to become a multi-trillion dollar market. The fund's technical indicators suggest near-term pressure with key support at $35.

The robotics and AI theme offers long-term growth potential as industrial automation and physical AI gain traction, though current technical weakness and market volatility present near-term risks. Positive industry catalysts include reshoring trends and AI's expansion into physical applications, but investors face sector rotation risks and competitive ETF landscape challenges.

Cassava Sciences Inc

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.

Returns comparison

Trailing returns across standard periods

About Global X Robotics and Artificial Intelligence ETF

The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.

Read more on BOTZ

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA